New Cancer Therapy Drug: Gilead; for the treatment of relapsed CLL, follicular B-cell NHL

Zydelig (idelalisib) is a small molecule inhibitor of phosphoinositide-3 kinase (PI3K) delta, an intracellular signaling component. PI3K-delta is expressed primarily in blood-cell lineages, including cells that cause or mediate hematologic malignancies.
Zydelig is specifically indicated for the following:

• Relapsed chronic lymphocytic leukemia in combination with rituximab, in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities.
• Relapsed follicular B-cell non-Hodgkin lymphoma in patients who have received at least two prior systemic therapies. 
• Relapsed small lymphocytic lymphoma in patients who have received at least two prior systemic therapies

Zydelig is supplied as a tablet for oral administration. The recommended maximum starting dose of Zydelig is 150 mg administered orally twice daily. Zydelig can be taken with or without food. Tablets should be swallowed whole. Continue treatment until disease progression or unacceptable toxicity.

Adverse effects associated with the use of Zydelig may include, but are not limited to, the following:
diarrhea
pyrexia
fatigue
nausea
cough
pneumonia
abdominal pain
chills
rash

For additional information regarding Zydelig or relapsed chronic lymphocytic leukemia, relapsed follicular B-cell non-Hodgkin lymphoma and relapsed small lymphocytic lymphoma, please visit www.zydelig.com